Opsona Therapeutics appoints chief medical officer
Chief executive steps down for personal reasons
Chief executive Dr Mark Heffernan has stepped down for personal reasons but will remain as a non-executive board member. Bernd Seizinger has been appointed executive chairman and will oversee the search for a new ceo and assume additional responsibilities for the company's operations during this period.
To further strengthen the executive management team, one of the company's founding scientists and directors, Professor Luke O'Neill will assume the additional role of chief scientific officer.
Opsona's vp of pharmaceutical development, Mary Reilly, has taken a broader role within the company as vice president of pharmaceutical development and operations.
You may also like
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development
AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment
AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy